Analysts expect Vitamin Shoppe, Inc (NYSE:VSI) to post $296.71 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Vitamin Shoppe’s earnings. The highest sales estimate is $296.94 million and the lowest is $296.47 million. Vitamin Shoppe posted sales of $314.89 million during the same quarter last year, which suggests a negative year-over-year growth rate of 5.8%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Vitamin Shoppe will report full-year sales of $296.71 million for the current financial year, with estimates ranging from $1.18 billion to $1.22 billion. For the next fiscal year, analysts anticipate that the business will report sales of $1.18 billion per share. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Vitamin Shoppe.

Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings results on Wednesday, August 9th. The specialty retailer reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by ($0.16). The company had revenue of $304.84 million for the quarter, compared to analyst estimates of $314.74 million. Vitamin Shoppe had a positive return on equity of 8.33% and a negative net margin of 11.98%. The firm’s quarterly revenue was down 8.4% on a year-over-year basis. During the same quarter last year, the company posted $0.55 earnings per share.

Several analysts have recently weighed in on VSI shares. Zacks Investment Research upgraded shares of Vitamin Shoppe from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine cut shares of Vitamin Shoppe from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Bank of America Corporation restated an “underperform” rating and set a $5.00 price objective (down previously from $5.50) on shares of Vitamin Shoppe in a research report on Wednesday, August 23rd. BidaskClub cut shares of Vitamin Shoppe from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Finally, Morgan Stanley restated an “equal weight” rating and set a $7.50 price objective (down previously from $8.00) on shares of Vitamin Shoppe in a research report on Monday, October 2nd. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Vitamin Shoppe currently has an average rating of “Hold” and an average price target of $9.92.

ILLEGAL ACTIVITY WARNING: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/brokerages-anticipate-vitamin-shoppe-inc-vsi-will-post-quarterly-sales-of-296-71-million.html.

Vitamin Shoppe (VSI) opened at 5.20 on Wednesday. Vitamin Shoppe has a one year low of $4.95 and a one year high of $28.41. The stock’s 50 day moving average is $5.40 and its 200 day moving average is $11.25. The firm’s market capitalization is $120.76 million.

In other Vitamin Shoppe news, Director John D. Bowlin bought 40,000 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were bought at an average price of $5.50 per share, for a total transaction of $220,000.00. Following the transaction, the director now directly owns 56,028 shares in the company, valued at $308,154. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.07% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA raised its position in Vitamin Shoppe by 2.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock worth $108,000 after purchasing an additional 192 shares during the period. Municipal Employees Retirement System of Michigan raised its position in Vitamin Shoppe by 18.1% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,410 shares of the specialty retailer’s stock worth $110,000 after purchasing an additional 1,440 shares during the period. Mason Street Advisors LLC raised its position in Vitamin Shoppe by 7.0% in the 1st quarter. Mason Street Advisors LLC now owns 5,569 shares of the specialty retailer’s stock worth $112,000 after purchasing an additional 366 shares during the period. Wolverine Trading LLC purchased a new position in Vitamin Shoppe in the 2nd quarter worth $131,000. Finally, UBS Asset Management Americas Inc. raised its position in Vitamin Shoppe by 17,041.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,999 shares of the specialty retailer’s stock worth $140,000 after purchasing an additional 11,929 shares during the period. Institutional investors own 96.86% of the company’s stock.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Get a free copy of the Zacks research report on Vitamin Shoppe (VSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.